Who are Aprepitant plus Olanzapine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aprepitant-plus-olanzapine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Aprepitant plus Olanzapine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Aprepitant plus Olanzapine (Aprepitant plus Olanzapine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NK1 receptor antagonist + atypical antipsychotic combination. Area: Oncology.

phase 3 NK1 receptor antagonist + atypical antipsychotic combination Neurokinin-1 (NK1) receptor; dopamine D2 receptor; serotonin 5-HT2A receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Aprepitant plus Olanzapine (Aprepitant plus Olanzapine) — Rush University Medical Center. Aprepitant blocks substance P neurokinin-1 receptors while olanzapine antagonizes dopamine and serotonin receptors, together providing enhanced antiemetic and anti-nausea effects.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Aprepitant plus Olanzapine TARGET	Aprepitant plus Olanzapine	Rush University Medical Center	phase 3	NK1 receptor antagonist + atypical antipsychotic combination	Neurokinin-1 (NK1) receptor; dopamine D2 receptor; serotonin 5-HT2A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NK1 receptor antagonist + atypical antipsychotic combination class)

Rush University Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aprepitant plus Olanzapine — Competitive Intelligence Brief. https://druglandscape.com/ci/aprepitant-plus-olanzapine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing